- Home
- VIR
as 11-22-2024 4:00pm EST
Vir Biotechnology Inc is an immunology company focused on combining cutting-edge technologies to treat and prevent serious infectious diseases and other serious conditions, including viral-associated diseases. Through internal development, collaborations, and acquisitions, it has four technology platforms, focused on antibodies, T cells, innate immunity, and small interfering ribonucleic acid, or siRNA. The company's pipeline consists of product candidates targeting hepatitis B, HBV, influenza A, human immunodeficiency virus, HIV, and tuberculosis, or TB. Its revenue sources are collaboration revenue, contract revenue, grant revenue, and license revenue.
| Founded: | 2016 | Country: | United States |
| Employees: | N/A | City: | SAN FRANCISCO |
| Market Cap: | 1.0B | IPO Year: | 2019 |
| Target Price: | $36.40 | AVG Volume (30 days): | 1.6M |
| Analyst Decision: | Buy | Number of Analysts: | 5 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -3.93 | EPS Growth: | N/A |
| 52 Week Low/High: | $6.56 - $13.09 | Next Earning Date: | 10-31-2024 |
| Revenue: | $78,618,000 | Revenue Growth: | -33.82% |
| Revenue Growth (this year): | -19.54% | Revenue Growth (next year): | -55.79% |
Stock Insider Trading Activity of Vir Biotechnology Inc. (VIR)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| de Verneuil Vanina | VIR | EVP and General Counsel | Nov 6 '24 | Sell | $10.11 | 4,397 | $44,453.67 | 56,973 | |
| de Verneuil Vanina | VIR | EVP and General Counsel | Nov 1 '24 | Sell | $8.34 | 3,750 | $32,332.22 | 56,973 | |
| Napolitano Janet | VIR | Director | Sep 9 '24 | Sell | $7.80 | 12,190 | $95,032.02 | 11,616 |
Latest Vir Biotechnology Inc. News
VIR Breaking Stock News: Dive into VIR Ticker-Specific Updates for Smart Investing
Business Wire
5 days ago
Vir Biotechnology Presents Positive Chronic Hepatitis Delta Clinical Trial Data and Announces Initiation of Phase 3 Registrational Program
Business Wire
5 days ago
Vir Biotechnology Receives Positive Opinion on Orphan Drug Designation for Tobevibart and Elebsiran in Chronic Hepatitis Delta from European Medicines Agency
Benzinga
8 days ago
What's Going On With Liver Disease Focused Vir Biotechnology Stock Is Friday?
Business Wire
8 days ago
Vir Biotechnology Announces Positive End-of-Treatment Results for Tobevibart and Elebsiran Combinations in Chronic Hepatitis B from the MARCH Study at AASLD The Liver Meeting
Argus Research
11 days ago
VIR: Lowering target price to $7.00
Argus Research
18 days ago
VIR: Rating decreased to a SELL
Simply Wall St.
20 days ago
Analysts Have Lowered Expectations For Vir Biotechnology, Inc. (NASDAQ:VIR) After Its Latest Results
Simply Wall St.
21 days ago
Vir Biotechnology Third Quarter 2024 Earnings: Misses Expectations
Compare VIR vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "VIR Vir Biotechnology Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.